Xilio Therapeutics, Inc.
XLO
$0.7002
-$0.031-4.24%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.72M | 2.26M | 2.36M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.72M | 2.26M | 2.36M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.72M | 2.26M | 2.36M | -- | -- |
| SG&A Expenses | 6.52M | 6.31M | 5.82M | 6.14M | 6.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.35M | 17.07M | 17.03M | 16.54M | 18.13M |
| Operating Income | -13.63M | -14.80M | -14.67M | -16.54M | -18.13M |
| Income Before Tax | -13.09M | -14.02M | -13.93M | -17.20M | -17.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.09M | -14.02M | -13.93M | -17.20M | -17.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.09M | -14.02M | -13.93M | -17.20M | -17.66M |
| EBIT | -13.63M | -14.80M | -14.67M | -16.54M | -18.13M |
| EBITDA | -13.25M | -14.42M | -14.23M | -16.10M | -17.68M |
| EPS Basic | -0.20 | -0.22 | -0.32 | -0.62 | -0.64 |
| Normalized Basic EPS | -0.13 | -0.14 | -0.20 | -0.36 | -0.40 |
| EPS Diluted | -0.20 | -0.22 | -0.32 | -0.62 | -0.64 |
| Normalized Diluted EPS | -0.13 | -0.14 | -0.20 | -0.36 | -0.40 |
| Average Basic Shares Outstanding | 64.68M | 63.47M | 43.95M | 27.91M | 27.56M |
| Average Diluted Shares Outstanding | 64.68M | 63.47M | 43.95M | 27.91M | 27.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
